Regulatory MSD takes on Pfizer’s Prevnar with new Capvaxive approval PharmaphorumMSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 21, 2026) Pharmaphorum MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17. Infectious Disease Read full story Post navigation Previous: New biotech cAMPfield emerges with $180M to reshape IBD treatmentNext: Moderna flu vaccine wins unanimous support from FDA panel Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
